{
  "title": "A \"Shock and Awe\" Acquisition",
  "itunes:title": "A \"Shock and Awe\" Acquisition",
  "pubDate": "Tue, 01 Nov 2022 20:00:00 +0000",
  "guid": "342e1231-4573-4f88-ad26-92ff7dcb3c5c",
  "link": "https://fool.libsyn.com/a-shock-and-awe-acquisition",
  "itunes:image": "",
  "description": "<p>A 50% premium is a buyout price most investors would love to see. To acquire Abiomed, Johnson & Johnson was happy to pay it.</p> <p>(0:17) Bill Mann discusses:<br /> - Why he believes a \"shock and awe\" price was worth paying for J&J<br /> - How Abiomed strengthens the company's medical device portfolio<br /> - Amazon expanding its ad-free music library for Prime members<br /> - Signs that the retail giant is gunning for Spotify, Disney, and other entertainment companies</p> <p>(10:33)  Alison Southwick and Robert Brokamp discuss how shortcuts can make you a smarter saver.</p> <p>Companies discussed: JNJ, ABMD, AMZN, SPOT, DIS, PARA</p> <p>Host: Chris Hill<br /> Guest: Bill Mann, Alison Southwick, Robert Brokamp<br /> Producer: Ricky Mulvey<br /> Engineers: Tim Sparks, Rick Engdahl</p>",
  "content:encoded": "<p>A 50% premium is a buyout price most investors would love to see. To acquire Abiomed, Johnson & Johnson was happy to pay it.</p> <p>(0:17) Bill Mann discusses: - Why he believes a \"shock and awe\" price was worth paying for J&J - How Abiomed strengthens the company's medical device portfolio - Amazon expanding its ad-free music library for Prime members - Signs that the retail giant is gunning for Spotify, Disney, and other entertainment companies</p> <p>(10:33)  Alison Southwick and Robert Brokamp discuss how shortcuts can make you a smarter saver.</p> <p>Companies discussed: JNJ, ABMD, AMZN, SPOT, DIS, PARA</p> <p>Host: Chris Hill Guest: Bill Mann, Alison Southwick, Robert Brokamp Producer: Ricky Mulvey Engineers: Tim Sparks, Rick Engdahl</p>",
  "enclosure": "",
  "itunes:duration": "26:05",
  "itunes:explicit": false,
  "itunes:keywords": "",
  "itunes:subtitle": "A 50% premium is a buyout price most investors would love to see. To acquire Abiomed, Johnson & Johnson was happy to pay it. (0:17) Bill Mann discusses: - Why he believes a \"shock and awe\" price was worth paying for J&J - How Abiomed...",
  "itunes:episodeType": "full"
}